Table 3.

Baseline characteristics of patients randomized into the HALT-C clinical trial, and those of selected into the nested case–control study (NCC) at 3.8 years after randomization

	HALT-C	HALT-C NCC
	(n = 1002)	(n = 116)
Age at randomization, mean (SD)	50.2 (7.2)	51.7 (7.5)
Female, n (%)	289 (28.8)	26 (22.4)
Race/ethnicity, n (%)
White	717 (71.6)	70 (60.3)
Black	183 (18.3)	36 (31.0)
Hispanic	79 (7.9)	7 (6.0)
Other	23 (2.3)	3 (2.6)
Drinks (per week), mean (SD)	9.6 (16.4)	9.5 (14.5)
DCP (log2), mean (SD)	4.9 (0.9)	4.9 (1.0)
Cirrhosis present, n (%)	408 (40.7)	66 (56.9)
Randomized to treatment, n (%)	507 (50.6)	59 (50.9)
HCC diagnosed, n (%)	39 (3.9)	39 (33.6)